✦ LIBER ✦

Rimonabant: more than an anti-obesity drug?

✍ Scribed by B Costa

Book ID: 110009421
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 58 KB
Volume: 150
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bjp.0707139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Annexin 1: more than an anti-phospholipa

Annexin 1: more than an anti-phospholipase protein

✍ Luca Parente; Egle Solito 📂 Article 📅 2004 🏛 SP Birkhäuser Verlag Basel 🌐 English ⚖ 134 KB

The anti-obesity effect of rimonabant is

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

✍ B. Poirier; J.-P. Bidouard; C. Cadrouvele; X. Marniquet; B. Staels; S. E. O'Conn 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

Anti-drug monoclonal antibodies antagoni

Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin

✍ A. Balsari; S. Ménard; M. I. Colnaghi; M. Ghione 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 376 KB

Prevention of obesity—more than an inten

Prevention of obesity—more than an intention. Concept and first results of the Kiel Obesity Prevention Study (KOPS)

✍ Langnäse, K; Grund, A; Müller, M J; Asbeck, I; Mast, M 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 317 KB

More anti-Zionist than thou: An unlikely

More anti-Zionist than thou: An unlikely remedy — A reply to Joseph Agassi

✍ Yossi Yonah 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 344 KB

B cell depletion may be more effective t

B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt